Hypothesis

Intermittent fasting (IF) enhances the SIRT1-activating potential of NAD+ precursors (NR/NMN) by driving circadian upregulation of NAMPT, the rate‑limiting enzyme in the NAD+ salvage pathway.

Background

• NR raises blood NAD+ ~2.3‑fold more than NMN at 1,200 mg/day NR raises NAD+ over 2‑fold more than NMN but functional SIRT1 activation in humans remains inconsistent Do NAD+ Boosters Work?.
• SIRT1 deletion abolishes NMN benefits in mouse neurodegeneration and metabolism models NMN reverses D-galactose-induced neurodegeneration.
• Exercise raises muscle NAD+ 25‑30 % and mimics caloric restriction SIRT1 effects NAD+ Boosters Research.
• Brain NAD+ requires ≥4 weeks of NR to increase; short‑term dosing fails NR raises NAD+ over 2‑fold more than NMN.

Mechanistic Insight

IF triggers a daily fasting‑refeeding cycle that activates AMPK during fasting periods. AMPK phosphorylates and stabilizes NAMPT, increasing its transcriptional output via circadian CLOCK/BMAL1 binding. Consequently, NAD+ salvage flux spikes at the onset of the refeeding window, creating a transient NAD+ pool that is kinetically favored for SIRT1 engagement because:

1. SIRT1 has a low Km for NAD+ and is highly sensitive to rapid NAD+ rises.
2. The concurrent rise in AMP/ATP ratio sustains AMPK activity, which directly deacetylates and activates SIRT1 independent of NAD+ levels.
3. Circadian gating ensures that NAD+ synthesis aligns with peripheral clock genes that regulate mitochondrial biogenesis, amplifying SIRT1/PGC‑1α signaling.

Testable Predictions

1. In healthy adults, a 16:8 IF regimen combined with NR (1,200 mg/day) will produce a greater increase in muscle SIRT1 activity (measured by deacetylation of PGC‑1α) after 2 weeks than NR alone or IF alone.
2. The peak SIRT1 activity will occur 2‑4 hours after the first meal, coinciding with maximal hepatic NAMPT expression and NAD+ salvage flux.
3. Blocking AMPK with compound C will abolish the synergistic SIRT1 activation despite elevated NAD+.

Experimental Design

• Randomized, crossover trial (n=30) with four 2‑week arms: (a) placebo, (b) NR, (c) IF (16:8), (d) NR+IF.
• Washout 2 weeks.
• Primary outcome: muscle SIRT1 activity via immunoblot for acetyl‑PGC‑1α in vastus lateralis biopsies taken at baseline, 2 h post‑meal, and 24 h post‑fast.
• Secondary outcomes: plasma NAD+, NAMPT mRNA in PBMCs (qPCR), AMPK phosphorylation (p‑AMPKThr172), and functional measures (VO2max, cognitive Stroop).
• Pharmacologic sub‑study: subset receives AMPK inhibitor or placebo during the final 2 days of each arm.

Potential Outcomes & Falsifiability

• If NR+IF yields a statistically significant >30 % increase in SIRT1 activity over NR alone, and this increase is attenuated by AMPK inhibition, the hypothesis is supported.
• If SIRT1 activity does not differ between NR and NR+IF, or if AMPK inhibition does not blunt the effect, the hypothesis is falsified, indicating that circulating NAD+ elevation alone suffices or that other mechanisms dominate.

This integrates circadian metabolism, AMPK signaling, and NAD+ salvage to explain why preclinical SIRT1 benefits often fail to translate in continuous‑dosing human trials and proposes a concrete, falsifiable regimen to test synergy.